Clopidogrel is an inhibitor of platelet ADP P2Y12 receptors and currently used for prevention
of stent thrombosis. Despite certain clinical benefit using this drug in patients undergoing …

Background Gene variants contribute to variability in individual responsiveness to
clopidogrel and influence cardiovascular outcomes in Caucasian patients with acute …

Clopidogrel is an inactive prodrug that requires in vivo conversion in the liver by the
cytochrome P450 (CYP) 3A4 enzyme system to an active metabolite that exerts its …

Several polymorphisms in genes that encode platelet components (receptors or enzymes),
or cytochrome P450 enzyme isoforms, involved in clopidogrel metabolism, have been …

The P2Y12 inhibitors, clopidogrel, prasugrel, and ticagrelor, are administered in fixed doses
without laboratory monitoring. Randomized trials in acute coronary syndrome have shown …

A double‐blind crossover study was conducted in four CYP2C19 genotype–defined
metabolizer groups to assess whether increase in clopidogrel dosing can overcome …

Objectives: This study sought to determine whether the pharmacokinetic (PK) and
pharmacodynamic (PD) responses to high or standard clopidogrel loading doses (LDs) …

Background It has been suggested that clopidogrel may be less effective in reducing the rate
of cardiovascular events among persons who are carriers of loss-of-function CYP2C19 …

Content Clopidogrel, one of the most commonly prescribed medications, is a prodrug
requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on …

Background: Clopidogrel has been widely used to prevent recurrent ischemia in patients
with acute coronary syndrome (ACS). However, inter-individual variability in response to …